GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities | Synapse
December 5, 2025
GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities
Key Points
Hidradenitis Suppurativa shows potential improvement with GLP-1RAs, indicating benefits for patients.
Safety and efficacy of GLP-1 receptor agonists are critical for widespread adoption among HS patients.
Assessment of treatment outcomes indicates a need for further exploration of GLP-1RA's role.
Research supports the idea of GLP-1RAs as a novel therapeutic approach for managing HS and related conditions.
Abstract
GLP-1RAs represent a promising adjunctive or standalone treatment choice for those with HS and its related comorbidities. Further research is needed to establish their safety and efficacy in HS treatment. .